# A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)

> **NCT05769816** · PHASE2 · RECRUITING · sponsor: **The Second Affiliated Hospital of Chongqing Medical University** · enrollment: 120 (estimated)

## Conditions studied

- Chronic Hepatitis b
- Anti-PD-1 Antibody

## Interventions

- **DRUG:** Anti-PD-1 antibody
- **DRUG:** NAs

## Key facts

- **NCT ID:** NCT05769816
- **Lead sponsor:** The Second Affiliated Hospital of Chongqing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-10
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-09-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05769816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05769816, "A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05769816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*